Patterns of relapse following definitive treatment of head and neck squamous cell cancer by intensity modulated radiotherapy and weekly cisplatin.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 21074875.
- Also identified by DOI 10.1016/j.radonc.2010.10.015.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Eighty-three patients with oropharyngeal, hypopharyngeal or laryngeal cancer were treated with concomitant cisplatin 40 mg/m(2) once a week during the radiotherapy and IMRT up to a total dose of 70 Gy. The 2-year rate of local control, overall survival and disease specific survival were 84%, 82% and 89%, respectively. The corresponding 5-year Kaplan-Meier estimates were 79%, 69% and 76%.
Medical subject headings
- Antineoplastic Agents
- Cisplatin
- Radiotherapy, Intensity-Modulated